CONFERENCE CAHR 2020

BRITISH COLUMBIA CENTRE *for* EXCELLENCE *in* HIV/AIDS

Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples

Hanwei Sudderuddin[1], Zhong Dang[1], Anh Le[1], Tetyana Kalynyak[1], Rob Hollebakken[1], Kyle Cobarrubias[1], Jinny Choi[1], Weiyan Dong[1], Winnie W. Dong[1], Walter Scott[1], Kate Laird[1], Paul Sereda[1], Eric O. Freed[2], Zabrina L. Brumme[1,3], Chanson J. Brumme[1,4]

1. BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; 2. National Cancer Institute, Frederick, MD, USA; 3. Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; 4. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

Program ID#: BSP1.09

Presenting Author: Hanwei Sudderuddin
hsudderuddin@cfenet.ubc.ca

SFU FACULTY OF HEALTH SCIENCES

Providence HEALTH CARE How you want to be treated.

UBC

BRITISH COLUMBIA Ministry of Health

29th Annual Canadian Conference on HIV / AIDS Research

29e Congrés annuel canadien de recherche sure le VIH/sida

Conflict of Interest Disclosure

In the past 2 years I have been an employee of: **BC Centre for Excellence in HIV/AIDS, Faculty of Health Sciences, Simon Fraser University**

In the past 2 years I have been a consultant for: N/A

In the past 2 years I have held investments in the following pharmaceutical organizations, medical devices companies or communications firms: N/A

In the past 2 years I have been a member of the Scientific advisory board for: N/A

In the past 2 years I have been a speaker for: N/A

In the past 2 years I have received research support (grants) from: N/A

In the past 2 years I have received honoraria from: N/A

I agree to disclose approved and non-approved indications for medications in this presentation: **YES**

I agree to use generic names of medications in this presentation: **YES**

There are relationships to disclose: **NO**

Background

- *In vitro* studies suggest that mutations conferring resistance to HIV Integrase Strand transfer inhibitors (INSTI) can occur outside integrase, including in the *env* gene
- It remains unclear whether these mutations arise frequently *in vivo*
- We sought to identify mutations in gp41 associated with exposure to INSTI *in vivo u*sing a database of clinically-derived HIV-1 sequences

Participant selection, data collection and analysis



Analysis 1: Comparison of INT and gp41 amino acid frequencies in population-level datasets from INSTI-naïve vs. INSTI-treated participants

Analysis 2: Comparison of gp41 sequences in matched pre- and post-INSTI treatment sequences to identify putative positions under selective pressure

Study Design and Methods

- Retrospective analysis of integrase (INT) and gp41 sequences collected during physician-requested resistance genotyping in BC-CfE Drug Treatment Program (DTP) participants with subtype B HIV-1

- **Analysis 1: Population-level analysis of INT and gp41 amino acid frequencies in INSTI-naïve and INSTI-treated participants**
  - **The INSTI-treated group** comprised 146 individuals who had been exposed to INSTI for ≥3 months, but had detectable plasma viremia, where INT resistance genotyping indicated that their virus was susceptible to all INSTI (Stanford HIVdb v8.8; score <15)
  - HIV-1 gp41 genotyping was performed on these same samples (115 successfully sequenced)
  - **The INSTI-naïve comparison groups** comprised independent datasets of subtype B INT (N=2472) and gp41 (N=1222) sequences from INSTI-naïve individuals who had undergone clinical resistance genotyping
  - We compared amino acid frequencies at all INT and gp41 codons between INSTI-naïve and INSTI-treated participants; Fisher's exact test was used to identify Amino Acids significantly over- or under-represented between groups. Multiple comparisons were addressed using the Benjamini-Hochberg method (q-values)

- **Analysis 2: Identification of putative INSTI resistance mutations in gp41 selected by INSTI treatment**
  - **Pre-INSTI gp41 genotyping for INSTI-treated group:** Archived plasma collected prior to INSTI exposure were identified for all 115 INSTI-treated participants described above
  - gp41 genotyping was successful in 64 pre-INSTI samples
  - Pre- and post-INSTI treatment sequences from each participant were compared; mutations putatively selected for ("gained") and against ("lost") during INSTI treatment were identified in each sequence pair
  - The frequency of mutations "gained" and "lost" during INSTI treatment was summarized

Maximum likelihood phylogeny of gp41 sequences from INSTI-naïve and INSTI-treated participants (Analysis 1)



Phylogenetic tree of HIV subtype B gp41 sequences from INSTI-naïve (blue) and INSTI-treated (orange) participants. Sequences from both groups are dispersed throughout the tree and do not substantially cluster by group.

Participant demographic and clinical characteristics (Analysis 1)

Variable	INSTI-naïve (N=1222)	INSTI-treated (N=115)
Age (Years); Median [IQR]	38 [32.5 - 44.9]	51 [44.3 - 56.1]
Male Sex; N (%)	1064 (87%)	82 (71%)
Female Sex; N (%)	148 (12%)	33 (29%)
Unknown Sex; N (%)	10 (1%)	0 (0%)
Plasma Viral Load (log_{10} copies/mL); Median [IQR]	5.0 [4.5 - 5.3]	3.6 [2.9 - 4.5]
CD4 (cells/μL); Median [IQR]	290 [140 - 430]	350 [195 - 580]
raltegravir; N (%)	-	60 (52%)
elvitegravir; N (%)	-	34 (30%)
dolutegravir; N (%)	-	55 (48%)
Cumulative INSTI exposure (Months); Median [IQR]	-	32 [13 - 56]

gp41 polymorphisms in INSTI-naïve and INSTI-treated participants (Analysis 1)

AA	AA frequency (%)		OR	p-value	q-value
	INSTI-naïve	INSTI-treated			
I182V	50.3%	28.7%	0.40	9.1×10^{-6}	0.0085
H209R	52.5%	33.9%	0.47	1.9×10^{-4}	0.086

Amino acids with statistically significant ($q<0.2$) differences in frequency between INSTI-treated vs. -naïve individuals identified in Analysis 1. gp41 polymorphisms I182V and H209R were underrepresented in INSTI-treated compared to INSTI-naïve individuals. **No significant differences in AA frequencies were observed in INT.**

CONFERENCE CAHR 2020

BRITISH COLUMBIA CENTRE *for* EXCELLENCE *in* HIV/AIDS

SFU FACULTY OF HEALTH SCIENCES

Providence HEALTH CARE How you want to be treated.

UBC

BRITISH COLUMBIA Ministry of Health

gp41 consensus sequences and residues putatively associated with INSTIs (Analysis 1)



gp41 amino acid alignment of HXB2, pNL4-3, and the consensus sequences of the INSTI-naïve and INSTI-treated groups. gp41 polymorphisms identified in Analysis 1 are in **red** (I182V_H209R). gp41 amino acids selected by INSTI *in vitro* (Env-A539V_A556T_R786K_I744V) identified in Van Duyne *et al. (PNAS, 2019)* are in **blue**. The gp41 resistance assay does not cover the final 20 amino acids of gp41.

Phylogeny relating pre- and post-INSTI treatment gp41 sequences (Analysis 2)



Phylogenetic tree of paired subtype B gp41 sequences collected before (red) and after (green) INSTI treatment. Pairing of pre- and post-therapy sequences from the same participants confirms that no obvious contamination or mix-ups occurred.

Putative sites in gp41 under selection during INSTI treatment (Analysis 2)

gp41 Codon	AA	Population frequency (%)	# gained	# lost
304	F	29.9%	6	5
122	R	71.4%	5	6
129	G	42.7%	5	3
157	N	25.7%	5	3
109	D	48.0%	4	4
182	V	50.3%	1	1
209	R	52.5%	1	1
30	V	0.15%	0	0
47	T	0.08%	0	0
235	V	8.8%	0	1
277	K	0.4%	0	1

Amino acids "gained" or "lost" in ≥4 participants while receiving INSTI-based therapy

Amino acids identified in **Analysis 1**

Env-A539V, A556T, R786K, I744V from Van Duyne *et al. (PNAS, 2019)*

Amino acids "gained" or "lost" in ≥4 participants in a comparison of gp41 sequences collected before and after INSTI treatment (grey shading). Sites under putative INSTI selection pressure were highly polymorphic in the INSTI-naïve population. Gain/loss of amino acids identified in Analysis 1 (pink shading) and by Van Duyne *et al* (orange shading) are also shown.

Conclusions

- gp41 substitutions previously associated with INSTI resistance *in vitro* were not enriched in INSTI-treated individuals vs. INSTI-naïve controls, nor were they observed to be selected during INSTI treatment
- Comparison of gp41 sequences from INSTI-naïve vs. INSTI-treated individuals identified two amino acids that were significantly underrepresented among the INSTI-treated group (Analysis 1), but these common polymorphisms were not frequently "lost" during INSTI treatment (Analysis 2)